公开(公告)号：US06818627B1

公开(公告)日：2004-11-16

申请号：US09485421

申请日：2000-10-05

申请人： Sundarasamy Mahalingam ,  Velpandi Ayyavoo ,  Mamata Patel ,  Thomas Kieber-Emmons ,  David B. Weiner

发明人： Sundarasamy Mahalingam ,  Velpandi Ayyavoo ,  Mamata Patel ,  Thomas Kieber-Emmons ,  David B. Weiner

IPC分类号： A61K4800

CPC分类号： C07K14/005 ,  A61K47/64 ,  A61K47/6901 ,  A61K48/00 ,  A61K2039/53 ,  C12N2740/16322 ,  G01N33/56988 ,  G01N2500/00

摘要： Conjugated compositions comprising a fragment of HIV-1 Vpr or a non-HIV-1 Vpr protein conjugated to a therapeutic compound and methods of using the same to deliver therapeutic compounds to a cell's nucleus or for the preparation of drug delivery particles are disclosed. Functional fragments of HIV-1 Vpr and functional non-HIV-1 Vpr proteins, and pharmaceutical compositions comprising the same are disclosed. Methods of inhibiting cell proliferation and methods of treating an individual who has a hyperproliferative disease are disclosed. Methods of identifying compounds that inhibit Vpr protein binding to the p6 domain of p55 or to p6 protein and kits for performing such methods are disclosed.

摘要翻译： 公开了包含与治疗性化合物缀合的HIV-1Vpr片段或非HIV-1Vpr蛋白的片段的共轭组合物及其使用方法将治疗性化合物递送至细胞核或用于制备药物递送颗粒。 公开了HIV-1Vpr和功能性非HIV-1 Vpr蛋白的功能片段和包含其的药物组合物。 公开了抑制细胞增殖的方法和治疗具有过度增殖性疾病的个体的方法。 公开了鉴定抑制Vpr蛋白与p55或p6蛋白的p6结构域结合的化合物的方法和用于进行这些方法的试剂盒。

公开(公告)号：US06448078B1

公开(公告)日：2002-09-10

申请号：US09529245

申请日：2000-10-17

申请人： David B. Weiner ,  Velpandi Ayyavoo ,  Sundarasamy Mahalingam ,  Mamata Patel

发明人： David B. Weiner ,  Velpandi Ayyavoo ,  Sundarasamy Mahalingam ,  Mamata Patel

IPC分类号： C12N506

CPC分类号： C07K14/705 ,  A61K38/00 ,  A61K48/00 ,  G01N33/6893 ,  G01N2500/04 ,  Y10S435/974

摘要： The present invention is directed to substantially pure Human Vpr Interacting Protein (hVIP), and fragments thereof. Also disclosed are isolated nucleic acid molecules that encode hVIP, or a fragment thereof; nucleic acid probes and primers directed to nucleic acid molecules that encode hVIP, or a fragment thereof; oligonucleotide molecules that consist of a nucleotide sequence complementary to a portion of the nucleotide sequence that encodes hVIP; vectors comprising nucleic acid molecules encoding hVIP; recombinant expression vectors that comprise nucleic acid sequences that encode hVIP; host cells that comprise recombinant expression vectors which include nucleic acid sequences that encode hVIP; genetic therapy vectors comprising nucleic acid molecules encoding hVIP; isolated antibody which binds to an epitope on hVIP; pharmaceutical compositions comprising a pharmaceutically acceptable carrier and nucleic acid molecules complementary to a portion of hVIP; methods of making hVIP; and methods of inhibiting expression of hVIP oligonucleotides complementary to a portion of the nucleotide sequence that encodes hVIP.

摘要翻译： 本发明涉及基本上纯的人Vpr交互蛋白（hVIP）及其片段。 还公开了编码hVIP或其片段的分离的核酸分子; 指向编码hVIP的核酸分子的核酸探针和引物或其片段; 由与编码hVIP的核苷酸序列的一部分互补的核苷酸序列组成的寡核苷酸分子; 包含编码hVIP的核酸分子的载体; 包含编码hVIP的核酸序列的重组表达载体; 包含重组表达载体的宿主细胞，其包括编码hVIP的核酸序列; 包含编码hVIP的核酸分子的遗传疗法载体; 分离的抗体，其结合hVIP上的表位; 包含药学上可接受的载体和与一部分hVIP互补的核酸分子的药物组合物; 制作hVIP的方法; 以及抑制与编码hVIP的核苷酸序列的一部分互补的hVIP寡核苷酸表达的方法。

公开(公告)号：US20070071755A1

公开(公告)日：2007-03-29

申请号：US11235337

申请日：2005-09-27

申请人： David Balasundaram ,  Du Xianming ,  Sundarasamy Mahalingam

发明人： David Balasundaram ,  Du Xianming ,  Sundarasamy Mahalingam

IPC分类号： A61K39/395 ,  C12Q1/68 ,  G01N33/574 ,  C12N9/16 ,  C07H21/04 ,  C12P21/06

CPC分类号： C12N9/16

摘要： There is provided an isolated polypeptide comprising an amino acid sequence at least 85% homologous to SEQ ID NO: 2 or SEQ ID N: 4, or a conservative variant thereof, wherein the polypeptide regulates proliferation of a cell. There is also provided an isolated polynucleotide encoding the polypeptide of the invention. There is also provided a method for inhibiting the proliferation of a cell, comprising altering the level of a polypeptide comprising an amino acid sequence at least 85% homologous to SEQ ID NO: 2 or SEQ ID NO: 4 in the cell, thereby inhibiting proliferation of the cell.

摘要翻译： 提供了分离的多肽，其包含与SEQ ID NO：2或SEQ ID NO：4或其保守变体至少85％同源的氨基酸序列，其中所述多肽调节细胞的增殖。 还提供了编码本发明多肽的分离的多核苷酸。 还提供了抑制细胞增殖的方法，包括改变包含与细胞中SEQ ID NO：2或SEQ ID NO：4至少85％同源的氨基酸序列的多肽的水平，由此抑制增殖 的细胞。

公开(公告)号：US20060088551A1

公开(公告)日：2006-04-27

申请号：US10953393

申请日：2004-09-29

申请人： Sundarasamy Mahalingam ,  Velpandi Ayyavoo ,  Mamata Patel ,  Thomas Kieber-Emmons ,  David Weiner

发明人： Sundarasamy Mahalingam ,  Velpandi Ayyavoo ,  Mamata Patel ,  Thomas Kieber-Emmons ,  David Weiner

IPC分类号： C12P21/06 ,  A61K39/12

CPC分类号： C07K14/005 ,  A61K47/64 ,  A61K47/6901 ,  A61K48/00 ,  A61K2039/53 ,  C12N2740/16322 ,  G01N33/56988 ,  G01N2500/00

摘要： Conjugated compositions comprising a fragment of HIV-1 Vpr or a non-HIV-1 Vpr protein conjugated to a therapeutic compounds and methods of using the same to deliver therapeutic compounds to a cell's nucleus or for the preparation of drug delivery particles are disclosed. Functional fragments of HIV-1 Vpr and functional non-HIV-1 Vpr proteins, and pharmaceutical compositions comprising the same are disclosed. Methods of inhibiting cell proliferation and methods of treating an individual who has a hyperproliferative disease are disclosed. Methods of identifying compounds that inhibit Vpr protein binding to the p6 domain of p55 or to p6 protein and kits for performing such methods are disclosed.

摘要翻译： 公开了包含与治疗性化合物缀合的HIV-1 Vpr片段或非HIV-1Vpr蛋白的片段的共轭组合物及其使用方法将治疗性化合物递送至细胞核或用于制备药物递送颗粒。 公开了HIV-1Vpr和功能性非HIV-1 Vpr蛋白的功能片段和包含其的药物组合物。 公开了抑制细胞增殖的方法和治疗具有过度增殖性疾病的个体的方法。 公开了鉴定抑制Vpr蛋白与p55或p6蛋白的p6结构域结合的化合物的方法和用于进行这些方法的试剂盒。

公开(公告)号：US06949337B2

公开(公告)日：2005-09-27

申请号：US10208338

申请日：2002-07-29

申请人： David B. Weiner ,  Velpandi Ayyavoo ,  Sundarasamy Mahalingam ,  Mamata Patel

发明人： David B. Weiner ,  Velpandi Ayyavoo ,  Sundarasamy Mahalingam ,  Mamata Patel

IPC分类号： C12N15/09 ,  A01N43/04 ,  A61K38/00 ,  A61K39/21 ,  A61K39/395 ,  A61K48/00 ,  A61P35/00 ,  C07H21/04 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/02 ,  G01N33/68 ,  C12Q1/70 ,  C12P21/06 ,  C12Q1/68 ,  G01N33/00

CPC分类号： C07K14/705 ,  A61K38/00 ,  A61K48/00 ,  G01N33/6893 ,  G01N2500/04 ,  Y10S435/974

摘要： The present invention provides methods of identifying anti-HIV compound by contacting human Vpr Interacting Protein (hVIP), or a fragment thereof known to interact with Vpr, with Vpr, or a fragment thereof known to interact with hVIP in the presence of a test compound, and comparing the affinity of the hVIP or fragment thereof to the Vpr or fragment thereof in the presence of the test compound with the affinity of the hVIP or fragment thereof to the Vpr or fragment thereof in the absence of the test compound. The present invention also provides transgenic non-human mammals comprising a recombinant expression vector that comprises a nucleic acid sequence that encodes hVIP.

摘要翻译： 本发明提供了通过将已知与Vpr相互作用的人Vpr相互作用蛋白（hVIP）或其片段与Vpr或其已知与hVIP相互作用的片段在测试化合物存在下接触来鉴定抗HIV化合物的方法 并且在不存在测试化合物的情况下，在测试化合物存在下，将hVIP或其片段与Vpr或其片段的亲和力与hVIP或其片段与Vpr或其片段的亲和力进行比较。 本发明还提供了包含重组表达载体的转基因非人哺乳动物，其包含编码hVIP的核酸序列。

公开(公告)号：US06172201B2

公开(公告)日：2001-01-09

申请号：US09418175

申请日：1999-10-13

申请人： David B. Weiner ,  Velpandi Ayyavoo ,  Sundarasamy Mahalingam ,  Mamata Patel

发明人： David B. Weiner ,  Velpandi Ayyavoo ,  Sundarasamy Mahalingam ,  Mamata Patel

IPC分类号： C07K1600

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K48/00 ,  A61K49/0041 ,  A61K49/0058 ,  A61K2039/53 ,  C07K14/705 ,  C07K2319/00 ,  C12N2740/16322 ,  G01N33/56988 ,  G01N2500/00

摘要： The present invention is directed to substantially pure human Vpr Interacting Protein (hVIP), and fragments thereof. Also disclosed are isolated nucleic acid molecules that encode hVIP, or a fragment thereof; nucleic acid probes and primers directed to nucleic acid molecules that encode hVIP, or a fragment thereof; oligonucleotide molecules that consist of a nucleotide sequence complementary to a portion of the nucleotide sequence that encodes hVIP; vectors comprising nucleic acid molecules encoding hVIP; recombinant expression vectors that comprise nucleic acid sequences that encode hVIP; host cells that comprise recombinant expression vectors which include nucleic acid sequences that encode hVIP; genetic therapy vectors comprising nucleic acid molecules encoding hVIP; isolated antibody which binds to an epitope on hVIP; pharmaceutical compositions comprising a pharmaceutically acceptable carrier and nucleic acid molecules complementary to a portion of hVIP; methods of making hVIP; and methods of inhibiting expression of hVIP oligonucleotides complementary to a portion of the nucleotide sequence that encodes hVIP.

摘要翻译： 本发明涉及基本上纯的人Vpr交互蛋白（hVIP）及其片段。 还公开了编码hVIP或其片段的分离的核酸分子; 指向编码hVIP的核酸分子的核酸探针和引物或其片段; 由与编码hVIP的核苷酸序列的一部分互补的核苷酸序列组成的寡核苷酸分子; 包含编码hVIP的核酸分子的载体; 包含编码hVIP的核酸序列的重组表达载体; 包含重组表达载体的宿主细胞，其包括编码hVIP的核酸序列; 包含编码hVIP的核酸分子的遗传疗法载体; 分离的抗体，其结合hVIP上的表位; 包含药学上可接受的载体和与一部分hVIP互补的核酸分子的药物组合物; 制作hVIP的方法; 以及抑制与编码hVIP的核苷酸序列的一部分互补的hVIP寡核苷酸表达的方法。

公开(公告)号：US6060587A

公开(公告)日：2000-05-09

申请号：US949202

申请日：1997-10-10

申请人： David B. Weiner ,  Velpandi Ayyavoo ,  Sundarasamy Mahalingam ,  Mamata Patel

发明人： David B. Weiner ,  Velpandi Ayyavoo ,  Sundarasamy Mahalingam ,  Mamata Patel

IPC分类号： C12N15/09 ,  A01N43/04 ,  A61K38/00 ,  A61K39/21 ,  A61K39/395 ,  A61K47/48 ,  A61K48/00 ,  A61K49/00 ,  A61P35/00 ,  C07H21/02 ,  C07H21/04 ,  C07K14/16 ,  C07K14/47 ,  C07K14/705 ,  C07K16/00 ,  C07K16/18 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/02 ,  G01N33/569 ,  C07K1/00 ,  C12Q1/68 ,  C07N21/04

CPC分类号： C07K14/005 ,  A61K49/0041 ,  A61K49/0058 ,  C07K14/705 ,  G01N33/56988 ,  A61K2039/53 ,  A61K38/00 ,  A61K48/00 ,  C07K2319/00 ,  C12N2740/16322 ,  G01N2500/00

摘要： The present invention is directed to substantially pure human Vpr Interacting Protein (hVIP), and fragments thereof. Also disclosed are isolated nucleic acid molecules that encode hVIP, or a fragment thereof; nucleic acid probes and primers directed to nucleic acid molecules that encode hVIP, or a fragment thereof; oligonucleotide molecules that consist of a nucleotide sequence complementary to a portion of the nucleotide sequence that encodes hVIP; vectors comprising nucleic acid molecules encoding hVIP; recombinant expression vectors that comprise nucleic acid sequences that encode hVIP; host cells that comprise recombinant expression vectors which include nucleic acid sequences that encode hVIP; genetic therapy vectors comprising nucleic acid molecules encoding hVIP; isolated antibody which binds to an epitope on hVIP; pharmaceutical compositions comprising a pharmaceutically acceptable carrier and nucleic acid molecules complementary to a portion of hVIP; methods of making hVIP; and methods of inhibiting expression of hVIP oligonucleotides complementary to a portion of the nucleotide sequence that encodes hVIP.

摘要翻译： 本发明涉及基本上纯的人Vpr交互蛋白（hVIP）及其片段。 还公开了编码hVIP或其片段的分离的核酸分子; 指向编码hVIP的核酸分子的核酸探针和引物或其片段; 由与编码hVIP的核苷酸序列的一部分互补的核苷酸序列组成的寡核苷酸分子; 包含编码hVIP的核酸分子的载体; 包含编码hVIP的核酸序列的重组表达载体; 包含重组表达载体的宿主细胞，其包括编码hVIP的核酸序列; 包含编码hVIP的核酸分子的遗传疗法载体; 分离的抗体，其结合hVIP上的表位; 包含药学上可接受的载体和与一部分hVIP互补的核酸分子的药物组合物; 制作hVIP的方法; 以及抑制与编码hVIP的核苷酸序列的一部分互补的hVIP寡核苷酸表达的方法。